ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Maximizing the Clinical Benefit of Crizitonib in NSCLC

Nicolas Girard, MD
Published Online:12:24 PM, Wed January 11, 2017

Nicolas Girard, MD, discusses how to maximize the clinical benefit of crizitonib (Xalkori) in non-small cell lung cancer (NSCLC). 
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.